The ABPI has appointed Andrew Hollingsworth as its new Policy Manager. He will take up the position on 25 November.
Andrew will report directly to the Head of Policy and Public Affairs, Audrey Yvernault, and will be responsible for leading the Association’s work with patient groups including its Patient Organisation Forum. He will also lead on policy coordination and development.
Andrew has a strong and extensive background in public affairs and policy in health and pharmaceuticals. He currently works as Public Affairs Manager at Cancer Research UK, engaging with EU and Westminster policymakers on a variety of issues including medical research, clinical trials and tobacco control.
Previously, Andrew worked in the European Public Affairs team of Novartis in Brussels, where he was responsible for implementing advocacy on EU pharmaceuticals policy and legislation for the company's Pharma and Consumer Health divisions. Prior to Novartis, he worked as a parliamentary assistant to a UK MEP, and previously held researcher positions at the London Assembly and House of Commons.
Commenting on his appointment, Andrew said:
"I am looking forward to joining the ABPI and making the case for the contribution of the industry to UK patients and the economy, including the benefits of fostering, and increasing access to, innovation. I am keen to develop the ABPI's engagement with patient organisations in an open, transparent and constructive dialogue."
Welcoming Andrew’s appointment Audrey Yvernault, Head of Policy and Public Affairs at the ABPI said:
“I am delighted that Andrew is joining the public affairs team, completing the ABPI’s investment in its policy and advocacy capabilities. His appointment will complement the existing team and enable us to further our advocacy goals on behalf of members”.
ABPI Press OfficeTel: +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064Email: [email protected]
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients.
Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.